Key result
ACS EuroPath II self-assessment tool helps physicians evaluate and optimize post-ACS lipid management.
Why the study?
Post-ACS patients remain at very high risk for recurrent events and mortality despite effective pharmacological options, with sub-optimal LDL-C management identified in Europe.
The ACS Lipid EuroPath tool offers a structured method for European cardiologists to self-assess and optimize lipid management in post-ACS patients in alignment with current guidelines.
Answers are grounded in this paper and cite their sources.
May facilitate post-ACS lipid management self-assessment; leaves open effects on adherence or outcomes.
Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. In 2018, the ACS EuroPath Survey, performed in collaboration with 555 European cardiologists, identified a sub-optimal LDL-C management in post-ACS patients. Based on these premises, the ACS EuroPath II project led to the development of a self-assessment tool to improve lipid management in these very high risk patients, taking into consideration the new 2019 ESC/EAS guidelines. This tool is built in 3 sections. The first is a questionnaire to assess the lipid management practice from the acute phase up to 12 months of follow-up. The main topics covered in this section relate to 1) acute phase (lipid management of ACS patients during hospitalization; 2) discharge (lipid management at discharge, with focus on follow-up plan); 3) follow-up (lipid management at the time of first and subsequent follow-ups); 4) referral pathway for definitive lipid management care of post-ACS patients; 5) evaluation of the achieved goal at 6 months to 1 year and key implications. The second section is a brief report to position the results against other European Union clinical practice and European guidelines. The last section allows the physician to evaluate and consider the implementation of one or more strategies, successfully developed in leading European centers, in order to optimize their own clinical practice.
No takes yet. Share an insight, caveat, or question.
Sionís et al. (2020) studied Acute Coronary Syndrome (n=555). ACS Lipid EuroPath tool was evaluated. The ACS EuroPath II project developed a 3-section self-assessment tool to help physicians evaluate and optimize lipid management practices for post-ACS patients according to 2019 ESC/EAS guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: